Puls-therapy with metilprednisolon in Grave's orbitopathy
https://doi.org/10.14341/ket20128447-52
Abstract
About the Authors
O Vinogradskayaaspirantka kafedry endokrinologii Pervogo MGMU im. I.M. Sechenov
D Lipatov
doktor med. nauk, zaveduyushchiy otdeleniem oftal'mologii FGBU “Endokrinologicheskiy nauchnyy tsentr” MZ RF
V Fadeev
doktor med. nauk, zamestitel' direktora FGBU “Endokrinologicheskiy nauch- nyy tsentr” MZ RF, professor kafedry endokrinologii Pervogo MGMU im. I.M. Sechenova
References
1. Bartalena L., Baldeschi L., Dickinson A.J. et al. Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy. Thyroid. 2008; 18 (3): 333–346.
2. Terwee C., Wakelkamp I., Tan S. et al. Long-term effects of Graves' ophthalmopathy on healthrelated quality of life. Eur. J. Endocrinol. 2002; 146: 751–757.
3. Wiersinga W.M., Kahaly G.J. Graves’ orbitopathy: a multidisciplinary approach. 2007; 260.
Review
For citations:
, , Puls-therapy with metilprednisolon in Grave's orbitopathy. Clinical and experimental thyroidology. 2012;8(4):47-52. (In Russ.) https://doi.org/10.14341/ket20128447-52

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).